CTOs on the Move

The Carolinas Center for Medical Excellence (CCM

www.mrnc.org

 
The Carolinas Center for Medical Excellence (CCME) is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mrnc.org
  • 100 Regency Forest Dr Ste 200
    Cary, NC USA 27518
  • Phone: 919.380.9860

Executives

Name Title Contact Details

Similar Companies

Harvest Technologies Corporation

Harvest Technologies Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plymouth, MA. To find more information about Harvest Technologies Corporation, please visit www.harvesttech.com

SIMMS AND MCIVOR

SIMMS AND MCIVOR is a Branchburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entrust Healthcare

Entrust Healthcare is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Delta Regional Medical Center

Delta Regional Medical Center has been committed to serving the citizens of Washington County and the outlying areas since our founding in the 1950s. Over time we have grown and progressed into a state-of-the-art hospital with a number of specialty

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.